Clinical trials recruiting in Santa Ana, California

Phase breakdown

Conditions recruiting in Santa Ana, California

Recruiting trials in Santa Ana, California

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  NCT07717411 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female)
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
  NCT06917404 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
  NCT06991114 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
  NCT07449702 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
  NCT06189963 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female)
• Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
  NCT07474792 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female)
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
  NCT07398417 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
  NCT06947993 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female)
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female)
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female)
• Tactile Pre-Visit Imagery
  NCT07719205 · Phase: Not applicable (e.g. observational or device study) · Ages: 4 Years to 10 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Santa Ana, California?

30 recruiting trials have at least one study site in Santa Ana, California.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.